Contribute Information
Can you contribute information about this project?
Contact the EWS Team
According to bank's website, the approved investment is for up to US$30.7 million (“IFC Loan”) to Popular Pharmaceuticals PLC. (“PPL” or the “Company” or the “Borrower”) in Bangladesh. Founded in 2006, PPL is a well-established, mid-sized pharmaceutical manufacturer in Bangladesh. The Company ranks 9th by revenue in Bangladesh pharma market. PPL belongs to Popular Group, which is a leading, family-owned healthcare conglomerate in Bangladesh with a 41-year track record across diagnostics, pharmaceuticals, hospitals, and medical education. The IFC Loan proceeds will be used to finance working capital, primarily for the procurement of raw materials, which are mostly imported. The transaction aims to ensure uninterrupted supply of essential medicines during a period of financial sector stress and credit tightening in Bangladesh. A long-term US$-denominated loan will enable the Company to navigate the current financial sector stress and credit tightness and maintain continuity of operations.
Environmental Category: B - Limited
IFC’s investment will support the import requirements of the Company.
IFC's Investment as Approved by the Board: US$ 20.00 million (loan)
The sponsors include Dr. Mostafizur Rahman and his children – Mr. Murtuza Rahman, Mr. Sardin Rahman, and Ms. Sadia Rahman (collectively referred to as the “Sponsors”). The Sponsors are the ultimate beneficial owners of the 100% of the shareholding in the Borrower.
| Private Actor 1 | Private Actor 1 Role | Private Actor 1 Sector | Relation | Private Actor 2 | Private Actor 2 Role | Private Actor 2 Sector |
|---|---|---|---|---|---|---|
| - | - | - | - | Popular Pharmaceuticals PLC. | Client | Education and Health |
Popular Pharmaceuticals PLC.
Project Team Leader: Mr. Safiul Azam
Title: Director, Finance and Accounts
Email: sazam@popularbd.com
ACCESS TO INFORMATION
You can submit a request for information disclosure at: https://disclosures.ifc.org/#/inquiries
If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.
ACCOUNTABILITY MECHANISM OF IFC/MIGA
The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org